Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
mig [2023/07/03 12:29] – [Migraine] sflitmanmig [2024/04/06 15:48] (current) – [Migraine] sflitman
Line 2: Line 2:
  
 Migraine is arguably the most common neurological condition, affecting up to 80% of adults at some time in their lives. Migraine is arguably the most common neurological condition, affecting up to 80% of adults at some time in their lives.
 +
 +We have no current trials enrolling for migraine, but new opportunities may be posted soon.
 +
 +<html><!--
  
 ^ Condition(s)  ^ Type of Drug  ^  Phase  ^  Add-On  ^  Placebo  ^  Duration  ^  Open-Label Extension  ^  ^ Condition(s)  ^ Type of Drug  ^  Phase  ^  Add-On  ^  Placebo  ^  Duration  ^  Open-Label Extension  ^
 | Adult episodic migraine preventive |  Oral Zavegepant  |  III  |  Yes  |  50%  |   24 weeks  | | Adult episodic migraine preventive |  Oral Zavegepant  |  III  |  Yes  |  50%  |   24 weeks  |
  
-<html><!--+
  
 --></html> --></html>
Line 19: Line 23:
 <div align=right> <div align=right>
  <table border=0 cellspacing=0>  <table border=0 cellspacing=0>
-  <tr><td>Joshua A. Tobin, MD, Director of Migraine Research</td></tr>  +    <tr><td>Stephen S. Flitman, MD, Medical Director</td></tr>
-  <tr><td>Stephen S. Flitman, MD, Medical Director</td></tr>+
  </table>   </table> 
 </div> </div>

Trace:

Print/export
QR Code
QR Code mig (generated for current page)